Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Nexium 40mg Once Daily vs Prevacid 30mg Twice a Day for Control of Severe GERD

This study has been completed.
Sponsor:
Collaborator:
AstraZeneca
Information provided by:
Digestive & Liver Disease Specialists
ClinicalTrials.gov Identifier:
NCT00295685
First received: February 22, 2006
Last updated: February 24, 2009
Last verified: February 2009

February 22, 2006
February 24, 2009
October 2005
Not Provided
The proportion of subjects who are successfully stepped-down to single-dose PPI therapy, defined as having no recurrence of heartburn or acid regurgitation 3 months after PPI step-down.
Same as current
Complete list of historical versions of study NCT00295685 on ClinicalTrials.gov Archive Site
Changes in GERD symptom scores, health related quality of life, ancillary medication expenditures, and predictors of successful step-down.
Same as current
Not Provided
Not Provided
 
Nexium 40mg Once Daily vs Prevacid 30mg Twice a Day for Control of Severe GERD
Single Dose Nexium 40MG QAM vs Lansoprazole 30mg BID for Control of Symptomatic GERD-A Double Blind Cross-Over Study

The purpose of this study is to determine if people taking lansoprazole two times a day to control severe GERD symptoms can be controlled just as well, if not better, by taking Nexium just once a day.

approximately 20% of patients taking first generation proton pump inhibitors (PPIs) are taking more than the standard approved dose. This dosing is required to attain adequate control of the gastric and intraesophageal pH in order to affect the desired clinical improvement. It is recognized that the b.i.d dosing strategy increases the intragastric pH control of <4 from approximately 12 hours to almost 16 hours. The refinement of the S isomer of omeprazole (Nexium)has led to a way to more effectively control acid exposure. Comparative trials with all the PPIs have shown significantly greater pH control of <4 and head to head comparisons as well as a recent crossover study. One study suggests that Nexium dosing contains approximately 16.5 hours of a pH control of <4. Conceivably, this duration of pH control suggests that b.i.d. dosing of other PPIs might be avoided. Furthermore, it suggests that patients currently taking b.i.d. PPIs might be successful candidates for conversion to q.d. Nexium. This would provide a considerable cost implication to health care plans and for patients who are responsible for paying for their PPI therapy. To date, esomeprazole has not been studied in comparison to b.i.d. dosing with other PPIs. There is pharmacologic evidence to suggest, however, that it is comparable. In this proposed study, we believe that by beginning with patients who were well controlled should make for a cleaner definition and a higher likelihood to demonstrate efficacy.

Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double-Blind
Primary Purpose: Treatment
GERD
Drug: Antacids
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
50
December 2007
Not Provided

Inclusion Criteria:

  • Previous diagnosis of severe GERD.
  • Male or female 18-80 years of age
  • Ability to read, understand and provide informed consent
  • GERD is Adequately controlled on BID lansoprazole as evidenced by GERD-HRQL score of </= 11
  • Females of childbearing potential must use an acceptable method of birth control for the duration of the study.

Exclusion Criteria:

  • Known contraindications to Nexium
  • Current or historical evidence of >3 cm histologically confirmed Barrett's metaplasia without current dysplasia, esophageal stricture or extraesophageal GERD symptoms.
  • Previous Esophageal gastric surgery
  • Pregnant or nursing Females
  • Clinically significant abnormal laboratory values
  • Medical condition that may be adversely impacted by participation in this study
  • History of or current drug or alcohol abuse
  • Known malignancy
  • Need for concurrent therapy with any acid suppressive therapy other than the study drug, antacids, alginates, NSAIDS, >165 mg ASA, prostaglandin analogs, prokinetic drug, antineoplastic agents, Ketoconazole, Itraconazole, Voriconazole, Clarithromycin, Telithromycin, HIV protease inhibitors, Rifampin, Phenobarbital, or Digoxin
  • Use of investigational drug or experimental device within 30 days prior to screening
Both
18 Years to 80 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00295685
IRUSESOM0159
Not Provided
Not Provided
Digestive & Liver Disease Specialists
AstraZeneca
Principal Investigator: David A Johnson, MD Digestive & Liver Disease Specialists
Digestive & Liver Disease Specialists
February 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP